Novo Nordisk Pharmatech named Pharma Supplier of the Year

Koege, Denmark:- Novo Nordisk Pharmatech A/S is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries and has been named High Quality Pharmaceutical Supplier of the year.

The Danish-based specialist is among the winners of the 2016 Corporate Livewire Healthcare & Life Science Awards, celebrating the most innovative and successful projects carried out around the world during the year.

These awards allow scientists and healthcare professionals to showcase their efforts and innovations and are in the industry and are given to individuals and companies whose work has benefited patients’ lives. Those eligible for healthcare awards included health administration, healthcare and insurance providers and pharmaceutical companies.

Astonishing achievements

Jake Powers, Corporate LiveWire’s Director of the 2016 Healthcare and Life Science Awards said he was astonished at the level of innovation and achievements shown by award winners.

Commenting on the Novo Nordisk win, Jake said: “Our judging panel at Corporate LiveWire considered the strengths of each shortlisted candidate, setting its sights firmly on the most ground breaking firms, teams and individuals who have transformed global healthcare.

“The Healthcare awards are important to us because it gives us the opportunity to promote medical research that has helped improve treatments around the world. Each winner in this guide has played a big part in biology, medicine, and life sciences. I look forward to seeing the global changes they make in the medical world over the next few years.”

About Novo Nordisk Pharmatech A/S

Novo Nordisk Pharmatech A/S was established in 1949 as FeF Chemicals, acquired by Novo Nordisk in 1986 and has been part of the pharmaceutical group since then. On 1 September 2015 the company’s name was changed to Novo Nordisk Pharmatech A/S. It is the leading worldwide supplier of recombinant insulin for cell growth media and pharmaceutical grade quaternary ammonium compounds (Quats) for the pharmaceutical, biopharmaceutical and personal care industries.

The company markets its diabetic care, hemophilia, growth hormone therapy, obesity, and hormone replacement therapy (HRT) products worldwide, with customers in more than 180 countries.

All Novo Nordisk Pharmatech products are manufactured to cGMP standards. The company has distinguished itself for global regulatory compliance, consistent high quality, extensive regulatory documentation, continuous availability, security of its global supply chain and high levels of service and support.

For Financial Year 2015, Novo Nordisk reported world sales totaling 107,927 million Danish kroner (DEK) with more than half of all sales recorded in North America.

About Corporate LiveWire Awards 2016

The Corporate LiveWire Awards represent the pinnacle of business achievement, championing the best in their respective fields. The magazine’s corporate awards cover the most important sectors of business, from Finance advisories, Funding providers to Law firms and specialist advisory companies that deal with mergers and acquisitions. The culmination of the awards is the Global Award, covering businesses of every type that have proven their excellence throughout the year.

The new Healthcare & Life Sciences Awards celebrate the most innovative and successful projects carried out around the world over the previous 12 months. Life Sciences are split into three main categories – biology, medicine and new sciences, in addition to highlighting the achievements of those within relevant sub-sections. Those eligible for an award in healthcare will include health administration, insurance providers, pharmaceuticals and the various different types of health care providers, including psychiatry, alternative treatments, convalescent care and burial services.

For more information see: www.corporatelivewire.com/awards.html